- Trial Phase
- Preclinical (IND-enabling studies)
- Time to Market
- Unknown — likely years away if it ever reaches market; next gate is an IND filing / first-in-human Phase 1 start, for which no date has been announced.
- Why 2/10
- No hard, dated catalyst is scheduled for HCW11-018b in the next ~12 months: it is a preclinical (IND-enabling) asset with no IND filing date announced and no clinical-trial record, so per the rubric it scores in the 0-2 preclinical band despite being the company's lead oncology program.
Treat HCW11-018b as a very early, high-risk story stock: the next share-moving events are an IND filing / Phase 1 start announcement (undated) plus the company's ongoing financings and Q2 2026 earnings. Watch the cash runway — the July 2026 $1.6M private placement summary says proceeds fund HCW9302's clinical trials and IND-enabling work for two preclinical assets (likely including 018b), and the company has disclosed substantial doubt about going concern. The $30 single-analyst price target (Maxim, Buy) sits far above the ~$3.20 price and looks stale; do not anchor to it.
Price Chart
Executive Summary
HCW11-018b is the lead T-cell engager of HCW Biologics (Nasdaq: HCWB), a micro-cap clinical-stage biopharma in Miramar, FL, developing "fusion immunotherapeutics" for cancer, autoimmune disease and senescence-related conditions. It is a preclinical, IND-enabling asset: an April 27, 2026 announcement reported mechanism-of-action data validating tissue factor as a target and showing potent antigen-specific anti-pancreatic-cancer activity in animal models, but no clinical trial exists yet and no IND/Phase 1 date is scheduled. The drug sits inside a company in acute financial stress — going-concern doubt disclosed in Q1 2026, a 1-for-6 reverse split (June 30, 2026), a Nasdaq delisting fight, and two dilutive private placements in 2026 (~$4.0M in May at $1.405/unit; $1.6M in July) — so the science is intriguing but the investment setup is highly speculative.
How It Works
HCW11-018b is a "T-cell engager": an engineered protein that grabs two things at once — a protein called tissue factor that sits on the surface of many solid tumor cells, and the body's own T-cells (a type of immune cell) — physically pulling the two together so the T-cell kills the cancer cell. The company's prior (first-generation) molecule HCW9218 used a similar tissue-factor hook but worked through natural-killer cells; HCW11-018b is designed to engage T-cells instead, targeting solid tumors like pancreatic cancer, which are normally very hard for this class of drug to reach.
Trial Status
No clinical trial for HCW11-018b appears in the ingested ClinicalTrials.gov data (the only HCW-prefixed trial on file is HCW9218, a different molecule in a Phase 2 pancreatic-cancer study sponsored by ImmunityBio). The April 27, 2026 corporate announcement was a mechanism-of-action and target-validation update: HCW11-018b reportedly penetrates the tumor microenvironment and shows potent, antigen-specific anti-pancreatic-cancer activity in preclinical models. The company says it is advancing IND-enabling studies for its preclinical assets, funded in part by the May and July 2026 private placements.
The Two-Sided Case
Upcoming Catalysts
- IND filing or first-in-human (Phase 1) announcement for HCW11-018b — undated, likely the single biggest share-price event for this drug.
- Q2 2026 earnings / cash-position update (company settled $2.8M of disputed payables in July 2026, per its 8-K).
- HCW9302 Phase 1 data and recommended Phase 2 dose (company targeted year-end 2026) — a separate program but the main near-term value driver for HCWB.
- Further financings / warrant exercises (potential dilution events).
- Nasdaq continued-listing compliance monitoring through Sept 22, 2026 window.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HCW Biologics Inc. Press Release HCWB ·Originating report